Tesamorelin, the peptide many lists name for belly fat, is FDA-approved only for people with HIV, and its label says it is not for weight loss. Most “best peptides for weight loss” lists mix medicines like that with compounds no one has tested for weight loss in people. This guide sorts them by what trials in people show.
Jump to: Comparison Tirzepatide vs semaglutide Tesamorelin Research peptides Retatrutide By goal Oral Women over 40 Safety Cost FAQ
What are the best peptides for weight loss?
Tirzepatide (Zepbound) and semaglutide (Wegovy) are the best-supported peptides for weight loss. Both are FDA-approved, and in the one head-to-head trial they took off 20.2% and 13.7% of body weight over 72 weeks. Retatrutide is next but not approved. The other peptides below have smaller trials or none.
How to read it. Large trials: hundreds or thousands of people, weight loss measured. Not for weight loss: approved for something else. No weight-loss trial: none found. The last column is a read of published research, not a safety rating.
| Peptide | US status | Weight loss in people | Human data |
|---|---|---|---|
| TirzepatideZepbound, Mounjaro | Approved for weight management (Zepbound). Prescription. | 20.2% of body weight at 72 weeks, against 13.7% on semaglutide (SURMOUNT-5, 751 adults). Up to 20.9% in SURMOUNT-1. | Large trials |
| SemaglutideWegovy, Ozempic, Wegovy pill | Approved for weight management (Wegovy injection and Wegovy pill). Ozempic is for type 2 diabetes. | 14.9% at 68 weeks (STEP 1). The Wegovy pill: 13.6% at 64 weeks (OASIS 4). | Large trials |
| LiraglutideSaxenda, Victoza | Approved for weight management (Saxenda). Victoza is for type 2 diabetes. | About 8% at 56 weeks (SCALE). Daily injection. | Large trials |
| RetatrutideInvestigational | Not approved. In phase 3 trials. | 17.6% to 25.0% at 80 weeks, against 3.9% on placebo (TRIUMPH-1). | Phase 3, not approved |
| TesamorelinEgrifta | Approved for extra abdominal fat in adults with HIV lipodystrophy. Not a weight-loss drug. | Visceral fat fell 15.2% while placebo rose 5.0% at 26 weeks in 412 people with HIV. Body weight stayed about the same. | Not for weight loss |
| CJC-1295 + ipamorelin | Not approved. Sold as research chemicals or compounded. | Raises growth hormone levels. No trial showing weight loss in people found. | No weight-loss trial |
| SermorelinGeref | Approved in 1997 for children with growth hormone deficiency, discontinued in 2008. Compounded versions are not approved. | No trial showing weight loss in adults found. | No weight-loss trial |
| 5-Amino-1MQ | Not approved. A small molecule, not a peptide. | Mouse studies only. No published human trials found. | Mostly animal |
| MOTS-c | Not approved. | Animal and exercise-physiology studies. No weight-loss trial in people found. | Mostly animal |
| AOD-9604 | Not approved. | Early company-run studies only. No published trial showing weight loss found. | No weight-loss trial |
Statuses as of October 2026. “Found” means a PubMed and web search in October 2026, not that no trial exists.
“Peptide” is a chemical category, not a type of medicine. Approved drugs like tirzepatide and unapproved research compounds share the word, which makes them look equal on a list. They are not. For a plain-English primer, see what peptides are.
Tirzepatide vs semaglutide: which works better for weight loss?
Tirzepatide beat semaglutide in the only head-to-head trial: 20.2% against 13.7% of body weight at 72 weeks (SURMOUNT-5, 751 adults without diabetes, open label).
More people on tirzepatide lost at least 10% of their weight (81.6% against 60.5%) and at least 20% (48.4% against 27.3%). Waist size fell 18.4 cm against 13.0 cm. Fewer people stopped for stomach side effects on tirzepatide (2.7% against 5.6%), though the trial wasn’t built to compare safety.
Semaglutide has the longer record and the heart data. In the SELECT trial, Wegovy cut major cardiovascular events by about 20% in adults with heart disease and overweight but not diabetes. Both drugs work through appetite: many people notice less hunger within weeks, while most of the weight comes off over 68 to 72 weeks in the trials.
Does tesamorelin work for belly fat?
In people with HIV, yes. Tesamorelin cut visceral fat 15.2% at 26 weeks while placebo rose 5.0% (412 patients, NEJM 2007). The fat returned after treatment stopped (AIDS 2008), and total body weight did not change.
The pivotal trials enrolled people with HIV, so use in anyone else is off-label. No approved peptide targets belly fat in people without HIV.
Do CJC-1295, ipamorelin and other research peptides work for weight loss?
A PubMed and web search in October 2026 found no randomized trial showing weight loss in people for CJC-1295, ipamorelin, sermorelin, 5-amino-1MQ, MOTS-c or AOD-9604.
Growth hormone-releasing peptides reliably raise growth hormone and IGF-1 levels, per a 2026 narrative review. That is a hormone change, not a weight-loss result. The 5-amino-1MQ results come from mice. A 2026 sports-medicine scoping review found most data on these compounds are animal studies and called their claimed benefits unsubstantiated in humans.
Details on the individual compounds: CJC-1295 and ipamorelin, 5-amino-1MQ, MOTS-c and SLU-PP-332 (a small molecule, not a peptide).
Is retatrutide approved for weight loss?
No. Retatrutide is investigational as of October 2026. It activates three receptors (GIP, GLP-1 and glucagon), and the phase 3 results are out.
How to read it. Results are average body weight change against placebo. Doses are weekly.
| Trial | Who | Weight loss |
|---|---|---|
| TRIUMPH-1NEJM | 2,339 adults with obesity and no diabetes, 80 weeks | 17.6%, 23.7% and 25.0% on 4, 9 and 12 mg, against 3.9% on placebo |
| TRIUMPH-2The Lancet | Adults with obesity and type 2 diabetes | 11.9%, 16.8% and 18.8%, against 5.1% on placebo |
Most side effects were stomach-related. Dysesthesia (odd skin sensations) appeared in 4 to 7% of people on retatrutide against 1% on placebo. Twelve percent on the 9 mg dose and 8% on the 12 mg dose stopped because of adverse events or death, against 5% on placebo. Knee pain and sleep apnea improved too.
A vial sold online as retatrutide is not the drug used in these trials. For the wider approval picture, see our fat loss peptides breakdown.
Which peptide for weight loss fits your goal?
How to read it. Find your goal in the left column. The middle column names the best-supported option, and the right column says what to know first.
| Your goal | Best-supported option | What to know |
|---|---|---|
| Most weight loss | Tirzepatide | 20.2% in SURMOUNT-5. Prescription only. Cash vials run $299 to $449 a month depending on dose (LillyDirect, October 2026). |
| Most data, heart benefit | Semaglutide | Longest record. About 20% fewer major cardiovascular events in SELECT, in adults with heart disease and overweight. |
| A pill instead of a shot | Wegovy pill or Foundayo | Wegovy pill: 13.6%, strict morning routine. Foundayo (orforglipron, not a peptide): 11.2%, no food rules. Full pill comparison. |
| Belly fat | Tesamorelin, only with HIV lipodystrophy | No approved peptide targets belly fat in people without HIV. Tirzepatide cut waist size 18.4 cm in SURMOUNT-5. |
| Keep muscle | No peptide has shown this | Lean mass loss is a known concern with GLP-1 drugs. Ask about protein, strength training and a DEXA scan. |
| Lowest monthly cost | Wegovy pill | $149 at the starting dose, up to $299 (cash, checked October 10, 2026). |
Are there oral peptides for weight loss?
Yes, one. The Wegovy pill (oral semaglutide) was approved for weight loss on December 22, 2025. Foundayo (orforglipron) followed on April 1, 2026, but it is a small molecule, not a peptide. Both need a prescription. No oral research peptide has weight-loss trial data.
See the oral GLP-1 pill comparison and our guide to which oral peptides have human trials.
What are the best peptides for weight loss for women over 40?
The approved GLP-1 peptides. Most participants in STEP 1 and SURMOUNT-1 were women. No peptide has been shown to treat menopause weight gain specifically.
Rapid weight loss can include lean mass, so ask your prescriber about protein, strength training and a DEXA scan, and about bone density if you are postmenopausal. More on this in our guide to peptides for women.
Are peptides for weight loss safe?
It depends on which kind. Approved GLP-1 drugs have known side effects and years of monitoring. Research peptides have little human safety data, and what is in the vial is not checked by the FDA.
How to read it. This lists reported effects, not a full label. Your prescriber has the complete list.
| Type | Reported effects and risks | Who should avoid |
|---|---|---|
| Approved GLP-1 drugsTirzepatide, semaglutide, liraglutide | Nausea, vomiting, diarrhea and constipation, most often when the dose goes up. Boxed warning for thyroid C-cell tumors (seen in rodents; human risk unknown). Pancreatitis and gallbladder disease are rare. | Anyone with a personal or family history of medullary thyroid cancer or MEN 2. Pregnancy. |
| TesamorelinEgrifta | Joint pain, injection-site reactions, abdominal pain and muscle pain. | Pregnancy. Active cancer. |
| Research peptidesSold online, not approved | Little human safety data. Water retention and insulin resistance are reported with growth hormone secretagogues, and the contents of online vials are unchecked. | Anyone under 18. Anyone pregnant or breastfeeding. |
Can peptides cause cancer? The thyroid warning on GLP-1 drugs comes from rodent studies, and whether it applies to people is not known. For most research peptides, long-term safety, including cancer risk, has not been studied in people.
Who should not use these: anyone under 18, anyone pregnant, breastfeeding or planning a pregnancy, and tested athletes. Growth hormone-releasing peptides, including CJC-1295, ipamorelin, sermorelin and tesamorelin, are prohibited in sport.
How much do peptides for weight loss cost?
Cash prices for approved weight-loss peptides start at $149 a month for the Wegovy pill and $299 for Zepbound vials, as of October 2026. Insurance often covers these drugs for diabetes but not always for weight loss.
How to read it. Prices are manufacturer cash prices without insurance and change often. Check the manufacturer page before you plan around one.
| Option | Monthly cash price | Notes |
|---|---|---|
| Wegovy pillNovoCare | $149 to $299 | $149 at 1.5 mg, $199 at 4 mg, $299 at 9 mg and 25 mg. Checked October 10, 2026. |
| FoundayoLillyDirect | $149 to $349 | Reduced prices run through December 31, 2026. Not a peptide. |
| Zepbound vialsLillyDirect | $299 to $449 | $299 at 2.5 mg, $399 at 5 mg, $449 at 7.5 to 15 mg. |
| With coverage | As low as $25 | Commercial savings cards, if your plan covers the drug. Medicare’s GLP-1 Bridge costs $50 a month from July 2026 to December 2027 for those who qualify. |
Pill prices come from our oral GLP-1 guide.
Can you buy peptides for weight loss online or over the counter?
Not the approved ones. Tirzepatide, semaglutide, liraglutide and Foundayo all need a prescription, and no over-the-counter product is approved for weight loss. Products sold online as “research use only” are not approved, are labeled not for human consumption and are not made to drug standards.
- No certificate of analysis tied to a batch number and a named lab.
- Prices far below the market.
- Medical claims on the site.
- Crypto or gift-card-only payment.
- No physical business address.
A certificate of analysis shows only what one lab found in one batch. Learn how to verify a peptide COA, read the peptide scams to avoid, or see how we test and rank sellers on the peptide vendors page.
Peptides for weight loss: frequently asked questions
What’s the best peptide for weight loss?
Tirzepatide (Zepbound) is the best-supported peptide for weight loss: 20.2% of body weight at 72 weeks in SURMOUNT-5, against 13.7% for semaglutide. Both need a prescription. Retatrutide showed up to 25.0% at 80 weeks but is not approved as of October 2026.
What’s the best peptide for fat loss?
No peptide is approved to cut fat without cutting weight. Tirzepatide and semaglutide lower weight and waist size. Tesamorelin lowers visceral fat but is approved only for adults with HIV lipodystrophy and does not change body weight.
Do peptides for weight loss work?
The approved GLP-1 peptides do: 13.7% to 20.2% over 68 to 72 weeks in large trials. For CJC-1295, ipamorelin, sermorelin, 5-amino-1MQ, MOTS-c and AOD-9604, a PubMed and web search in October 2026 found no published trial showing weight loss in people.
Are peptides for weight loss the same as Ozempic?
Some are. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are GLP-1-based peptide medicines. “Peptide” is a chemical category, so research peptides like CJC-1295 share the word but are not GLP-1 drugs and are not approved.
Are peptides for weight loss safe?
It depends on the peptide. Approved GLP-1 drugs have known side effects, mostly nausea and other stomach effects, and a boxed warning about thyroid tumors seen in rodents. Research peptides have little human safety data and unchecked contents.
Are there oral peptides for weight loss?
One is approved: the Wegovy pill (oral semaglutide), approved December 22, 2025. Foundayo (orforglipron), approved April 1, 2026, is a small molecule, not a peptide. Both need a prescription. No oral research peptide has weight-loss trial data.
Do you need a prescription for peptides for weight loss?
Yes for every approved one: Zepbound, Wegovy and the Wegovy pill, Saxenda and Foundayo. No over-the-counter product is approved for weight loss. Collagen peptide supplements are protein products, not GLP-1 drugs.
How much do peptides for weight loss cost?
Cash prices as of October 2026: Wegovy pill $149 to $299 a month, Zepbound vials $299 to $449, Foundayo $149 to $349. Commercial savings cards can lower the price to $25 for eligible plans. Prices change, so check the manufacturer.
Is there a best peptide stack for weight loss?
No trial supports stacking research peptides for weight loss, and adding unapproved compounds to a GLP-1 drug adds unknown interactions. Ask the prescriber of any approved drug before adding anything.
Sources
- Aronne et al. SURMOUNT-5, tirzepatide vs semaglutide, NEJM 2025: ACC journal scan
- Jastreboff et al. SURMOUNT-1, NEJM 2022: doi:10.1056/NEJMoa2206038
- Wilding et al. STEP 1, NEJM 2021: doi:10.1056/NEJMoa2032183
- Lincoff et al. SELECT, NEJM 2023: doi:10.1056/NEJMoa2307563
- Pi-Sunyer et al. SCALE, liraglutide 3.0 mg, NEJM 2015: doi:10.1056/NEJMoa1411892
- Falutz et al. Tesamorelin in HIV, NEJM 2007: doi:10.1056/NEJMoa072375; extension, AIDS 2008: doi:10.1097/QAD.0b013e32830a5058
- Retatrutide TRIUMPH-1, NEJM: doi:10.1056/NEJMoa2604169; TRIUMPH-2, The Lancet: doi:10.1016/S0140-6736(26)01861-1
- Vasylieva et al. Peptides in urology and sexual medicine, Sex Med Rev 2026: doi:10.1093/sxmrev/qeag078
- Tewari et al. Peptide supplements in sports medicine, Am J Sports Med 2026: doi:10.1177/03635465261464420
- FDA Egrifta (tesamorelin) label: accessdata.fda.gov. Sermorelin (Geref) notice: Federal Register 2013
- Zepbound cash prices: LillyDirect